Resistance mechanisms

$Genomic Insights into Pirtobrutinib Efficacy and Resistance Mechanisms in Relapsed/Refractory Chronic Lymphocytic Leukemia$

Hematology-Oncology news

Genomic Insights into Pirtobrutinib Efficacy and Resistance Mechanisms in Relapsed/Refractory Chronic Lymphocytic Leukemia

By MedXY 10/14/2025

This article explores genomic factors influencing response and resistance to pirtobrutinib, a reversible BTK inhibitor, in relapsed/refractory CLL patients previously treated with covalent BTK inhibitors, highlighting clonal mutation dynamics and resistance without clear drivers.